Could a common b vitamin tame fatty liver?
NCT ID NCT07740109
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This trial tests whether a daily supplement of 5-methyltetrahydrofolate (a form of folate) can improve markers of liver health in people with metabolic dysfunction-associated steatotic liver disease (MASLD), a common type of fatty liver. Over 90 days, participants receive either the supplement or a placebo. Researchers will measure changes in blood folate, homocysteine, liver enzymes, and the activity of genes linked to inflammation and fat metabolism.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 5-methyltetrahydrofolate (5-MTHF), a form of folate, taken as an 800 mcg tablet daily for 90 days
- What this could lead to
- If it works, this could point toward a simple, safe supplement to help manage fatty liver disease and lower heart-risk markers.
- What could go wrong
- This is a small, early-stage trial, so results may not apply broadly. The supplement may not change liver health or gene activity as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASLD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Liver Clinic of Valiasr Hospital (Tabriz, Iran)
Tabriz, Iran
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Seaweed extract may tackle fatty liver Disease—A trial puts it to the test
- Can Weight-Loss surgery rewire the Liver's energy engine?
- Wheat sensitivity linked to fatty liver? a new study investigates
- Hidden liver risk in type 1 diabetes: a new study investigates
- Heart scans could flag Who's at risk after liver shunt